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Sensorimotor gating is associated with CHRNA3 polymorphisms
in schizophrenia and healthy volunteers
Abstract
Attentional gating deficits, commonly measured by prepulse inhibition (PPI) of the acoustic startle
response (ASR), have been established as an endophenotype of schizophrenia. PPI is heritable and has
been associated with polymorphisms in serotonin and dopamine system genes. PPI can be enhanced by
nicotine, and therefore it has been proposed that schizophrenia patients smoke to ameliorate their early
attentional deficits. The PPI-enhancing effects of nicotine in rodents are strain-dependent, suggesting a
genetic contribution to PPI within the nicotinic acetylcholine receptor (nAChR) system. Recent human
genetic studies also imply that tobacco dependence is affected by polymorphisms in the α3/α5 subunits
of the nAChR (CHRNA3/CHRNA5) gene cluster. We therefore investigated the impact of two common
CHRNA3 polymorphisms (rs1051730/rs1317286) on PPI, startle reactivity, and habituation of the ASR
in two independent samples of 107 British healthy volunteers and 73 German schizophrenia patients. In
both samples, PPI was influenced by both CHRNA3 polymorphisms (combined p-value 0.0027), which
were strongly linked.. Moreover, CHRNA3 genotype was associated with chronicity, treatment, and
negative symptoms in the schizophrenia sample. These results suggest that sensorimotor gating is
influenced by variations of the CHRNA3 gene, which might also have an impact on the course and
severity of schizophrenia.
Sensorimotor gating is associated with CHRNA3 polymorphisms 
in schizophrenia and healthy volunteers 
 
 
Nadine Petrovsky* (1), Boris B. Quednow*,† (2), Ulrich Ettinger (3), Anne Schmechtig (4), 
Rainald Mössner (1), David A. Collier (5), Kai-Uwe Kühn (1), Wolfgang Maier (1), 
Michael Wagner (1), and Veena Kumari (4) 
 
(1) Department of Psychiatry and Psychotherapy, University of Bonn, Germany 
(2) University Hospital of Psychiatry, Division of Experimental and Clinical Pharmacopsychology, University 
of Zurich, Switzerland 
(3) Department of Psychiatry and Department of Psychology, Ludwig-Maximilians University Munich, 
Germany 
(4) Department of Psychology, Institute of Psychiatry, King's College London, London, United Kingdom  
(5) Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, King’s College London, 
United Kingdom  
 
*these authors contributed equally 
 
 
Abbreviated Running Title: 
CHRNA3 and sensorimotor gating 
 
 
Manuscript Category: 
Original Article 
 
 
Resubmitted: 
December 10th, 2009 
 
 
Manuscript Characteristics: 
Number of words in the abstract: 194 
Number of words in the text: 4040 
Number of references: 82 
Number of figures: 1 
Number of tables: 3 
 
 
 
†Corresponding Author:  
Boris B. Quednow, Ph.D., Dipl.-Psych. 
University Hospital of Psychiatry 
Experimental and Clinical Pharmacopsychology 
Lenggstrasse 31 
CH-8032 Zurich, Switzerland 
Tel.: 0041-44-384-2777 
Fax: 0041-44-384-2499 
E-Mail: quednow@bli.uzh.ch 
  2
Abstract 
Attentional gating deficits, commonly measured by prepulse inhibition (PPI) of the acoustic 
startle response (ASR), have been established as an endophenotype of schizophrenia. PPI is heritable 
and has been associated with polymorphisms in serotonin and dopamine system genes. PPI can be 
enhanced by nicotine, and therefore it has been proposed that schizophrenia patients smoke to 
ameliorate their early attentional deficits. The PPI-enhancing effects of nicotine in rodents are strain-
dependent, suggesting a genetic contribution to PPI within the nicotinic acetylcholine receptor 
(nAChR) system. Recent human genetic studies also imply that tobacco dependence is affected by 
polymorphisms in the α3/α5 subunits of the nAChR (CHRNA3/CHRNA5) gene cluster. We therefore 
investigated the impact of two common CHRNA3 polymorphisms (rs1051730/rs1317286) on PPI, 
startle reactivity, and habituation of the ASR in two independent samples of 107 British healthy 
volunteers and 73 German schizophrenia patients. In both samples, PPI was influenced by both 
CHRNA3 polymorphisms (combined p-value 0.0027), which were strongly linked.. Moreover, 
CHRNA3 genotype was associated with chronicity, treatment, and negative symptoms in the 
schizophrenia sample. These results suggest that sensorimotor gating is influenced by variations of the 
CHRNA3 gene, which might also have an impact on the course and severity of schizophrenia. 
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Introduction 
Prepulse inhibition (PPI) of the acoustic startle response is defined as the suppression of the 
startle reflex that occurs when a relatively weak and non-startling sensory event (the prepulse) is 
presented 30-500 ms before a strong startle-eliciting stimulus (the pulse) (Graham, 1975). PPI has 
been firmly established as an operational measure of sensorimotor gating because it is thought to 
regulate sensory input by filtering or “gating out” excess or irrelevant stimuli in order to prevent 
sensory information overflow (Braff et al, 2001). PPI is regulated by a cortico-striato-pallido pontine 
(CSPP) circuitry including frontal and mediotemporal brain regions, the ventral striatum, the ventral 
pallidum and pontine regions of the brainstem (Koch, 1999; Swerdlow et al, 2001). Lesion studies and 
pharmacological challenge studies in rodents have revealed that dopamine, serotonin, glutamate, and 
acetylcholine are involved in the mediation of PPI (Geyer et al, 2001; Swerdlow et al, 2001). Recent 
association studies in healthy humans and schizophrenia patients now suggest that genetic variations 
of the serotonin-2A receptor (5-HT2AR), the catechol-O-methyltransferase (COMT) and the dopamine-
D3 receptor (DRD3) may all affect PPI (Quednow et al, 2008b; 2008c; 2009; Roussos et al, 2008a; 
2008b). However, it is most likely that each of these genetic polymorphisms only explains a fraction 
of the PPI variance and that further genes, including perhaps genes within the glutamate and 
acetylcholine system, also contribute to the variant expression of PPI. 
Several psychiatric and neurological disorders have been reported to present sensorimotor 
gating deficits (for review see Braff et al, 2001; and Quednow, 2008) but the most consistent findings 
are PPI deficits in schizophrenia spectrum disorder (Braff et al, 1978; 1992; Cadenhead et al, 1993; 
2000; Kumari et al, 2000; Ludewig et al, 2003; Parwani et al, 2000; Perry et al, 2002; Quednow et al, 
2006b; Swerdlow et al, 2006). The findings that PPI is heritable (Anokhin et al, 2003; Greenwood et 
al, 2007), that it is reduced in unaffected relatives of schizophrenia patients (Cadenhead et al, 2000; 
Kumari et al, 2005b), that it is influenced by polymorphisms within the dopamine and serotonin 
system (Quednow et al, 2008b; 2008c; 2009; Roussos et al, 2008a; 2008b), and that PPI deficits are 
present during the prodromal stage, before the clinical diagnosis of schizophrenia (Quednow et al, 
2008a) suggested that PPI is an important and valid candidate as an intermediate or endophenotypic 
marker in genetic studies of schizophrenia (Braff and Freedman, 2002; Gottesman and Gould, 2003). 
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Studies in humans (Baschnagel and Hawk, 2008; Della Casa et al, 1998; Duncan et al, 2001; 
Hong et al, 2008; Kumari et al, 1996; 1997) and animals (Acri et al, 1994; 1995; Curzon et al, 1994; 
Faraday et al, 1999; Schreiber et al, 2002; Spielewoy and Markou, 2004) have shown that the 
nicotinic acetylcholine receptor (nAChR) agonist nicotine enhances PPI. These findings, taken 
together with the notion that schizophrenia patients have a strongly increased likelihood of smoking 
(for review see Dalack et al, 1998; and Ripoll et al, 2004), have led to the “self-medication 
hypothesis”, which proposes that schizophrenia patients may attempt to transiently remedy otherwise 
deficient attentional processes; this effect, however, could vary depending on genetic background 
(Kumari and Postma, 2005). PPI studies also contribute to the view that neurocognitive dysfunction in 
schizophrenia could be based on a dysfunctional nAChR-system: George and coworkers (2006) 
demonstrated that tobacco smoking selectively enhances PPI deficits in schizophrenia and more 
recently it was also shown that nasally administered nicotine increases PPI in schizophrenia patients 
and healthy controls (Hong et al, 2008). Interestingly, the PPI-enhancing effects of nicotine in 
schizophrenia patients could be dose-dependently blocked by the non-competitive and non-selective 
nAChR antagonist mecamylamine, which suggests that this effect is mediated through activation of 
central nAChR (George et al, 2006). Given that mecamylamine antagonises α3β2, α3β4, α4β2, and α7 
nAChRs but that its antagonism at the α7 subunit is not functional (Papke et al, 2001), the PPI-
increasing effects of nicotine are likely explained by an activation of α3β2, α3β4, and/or α4β2 
nAChRs (Sacco et al, 2005). Moreover, α7 nAChR knock-out mice display normal PPI levels and 
neither selective α7 nAChR agonists (GTS-21 and AR-R-17779) nor a selective α7 nAChR antagonist 
(methyllycaconitine) changed PPI in rodents (Schreiber et al, 2002; Suemaru et al, 2004), making it 
unlikely that α7 nAChRs significantly contribute to the normal regulation of PPI. At present, it is still 
unclear whether genetic variation in the nAChR system could have an impact on human PPI. 
However, the PPI-enhancing effects of nicotine in rodents appear to be strain-dependent, which points 
to a strong genetic modulation of this effect within the nAChR system (Curzon et al, 1994; Faraday et 
al, 1998; 1999; Schreiber et al, 2002; Spielewoy and Markou, 2004). 
Several recent studies have consistently shown that multiple SNPs (single nucleotide 
polymorphisms) within the α3/α5 nAChR subunit (CHRNA3/CHRNA5) gene cluster on chromosome 
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15q25.1 are strongly associated with nicotine dependence (Berrettini et al, 2008; Bierut et al, 2008; 
Caporaso et al, 2009; Saccone et al, 2009). Berettini and colleagues (2008) found that “cigarettes per 
day” (CPD) was associated with a common haplotype in the CHRNA3/CHRNA5 gene cluster in three 
independent populations of European origin totalling about 15,000 individuals. In particular, the SNPs 
rs578776, rs1051730, rs1317286 and rs6495308 were associated with CPD. A recent meta-analysis by 
Caporaso and colleagues (2009) further supports that diverse SNPs of the CHRNA3 and CHRNA5 
genes are associated with CPD, including rs1051730 in CHRNA3 (combined p=5*10-32). Furthermore, 
a meta-analysis of schizophrenia linkage studies suggested that chromosomal region 15q21.3–15q26.1 
may harbour illness-associated genes (Lewis et al, 2003), but presently it is unclear, whether there are 
genetic polymorphisms in the nAChR system which account for both the vulnerability to 
schizophrenia and smoking behavior. An altered nAChR system may lead to gating dysfunctions, 
which could be ameliorated by self-administered nicotine, and may at least explain a portion of the 
variance for the development of schizophrenia and/or smoking. We therefore assume that certain 
genetic polymorphisms of nAChR subunits similarly account for attentional endophenotypes in 
schizophrenia and nicotine dependence. 
Based on the findings from Berrettini et al (2008) and the meta-analysis by Caporaso et al 
(2009) we hypothesized that SNPs from the CHRNA3/CHRNA5 gene cluster would have an impact on 
sensorimotor gating, which is disturbed in schizophrenia and enhanced by nicotine. Given that the α3 
nAChR might be involved in the reversal of sensorimotor gating deficits in schizophrenia (George et 
al, 2006), we focused on SNPs of the CHRNA3 gene. We have chosen two of the four SNPs 
(rs1051730 and rs1317286) that were associated with cigarette smoking in the large study of Berettini 
et al. (2008) and that displayed the highest minor allele frequencies of approximately 30-40% in 
European-ancestry samples (Bierut et al, 2008; International HapMap Consortium, 2003; Saccone et 
al, 2009). We investigated two independent European Caucasian samples – a sample of 107 healthy 
volunteers recruited in London, United Kingdom, and a sample of 73 schizophrenia inpatients 
recruited in Bonn, Germany, to directly test for replicability of our findings. 
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Materials, Subjects and Methods 
Participants 
For the first experiment, 107 healthy Caucasian volunteers were recruited through local 
advertisements in South London, United Kingdom. Participants between 18 and 43 years of age were 
screened for the exclusion criteria of DSM-IV Axis I disorders using the Structured Clinical Interview 
for DSM-IV Disorders (SCID-I). Additional exclusion criteria were a history of head injuries, any 
known neurological abnormalities or systemic illness with known neurological complication, a first-
degree relative with psychosis or obsessive-compulsive disorder, and a history of substance abuse or 
dependence. Current smoking behaviour was assessed with the Fagerström Test for Nicotine 
Dependence (FTND) (Heatherton et al, 1991) and the number of cigarettes smoked per day (CPD). 
For the second experiment, 73 schizophrenia inpatients admitted to the psychiatric hospital of 
the University of Bonn, Germany, were considered eligible for the study if the following criteria were 
met: a diagnosis of schizophrenia according to DSM-IV, age between 18 and 65 years, and Caucasian 
ethnicity. Patients were excluded if they had a history of head injuries, a neurological disease, a 
history of substance abuse or dependency, or a severe somatic disease. Every patient was evaluated 
with the Structured Clinical Interview (SCID-I). Clinical symptoms were measured with the Positive 
and Negative Syndrome Scale (PANSS) (Kay et al, 1992). Fourteen patients were unmedicated, 12 
patients received a typical antipsychotic, 43 patients were treated with an atypical antipsychotic, three 
received two atypical drugs, and one received a typical and an atypical antipsychotic. Moreover, three 
of the patients received antidepressants and five were treated with benzodiazepines, which were 
tapered 24 h before startle testing. Current smoking status was assessed by the question: Do you 
smoke more than 10 cigarettes per week (yes: smoker/no: non-smoker)?  
For both samples, ethical approvals of the local ethics committees were obtained, and all 
participants provided written informed consent before inclusion. 
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Genotyping 
In the British healthy volunteers, SNP genotyping assays were run as submicroliter 
polymerase chain reaction–based assays on Array Tape (http://www.douglasscientific.com) at 
PreventionGenetics (Marshfield, Wisconsin). For the German schizophrenia patients, the SNPs were 
analyzed by Taqman Assays (Applied Biosystems, Foster City, California). Both procedures are 
described in detail in Supplementary material 1. 
 
Startle Response Measurement 
The two samples were assessed with slightly different PPI paradigms. Equipment, set up, PPI 
testing, and data acquisition and scoring procedures for both have previously been described in detail 
(London sample: Kumari et al, 2005a; Bonn sample: Quednow et al, 2006a; 2006b). 
In the London healthy volunteer sample, each examination began with a 4-min acclimation 
period of 70-dB background noise that was continued throughout the session. Participants received 49 
white noise sound pulses at an intensity of 115 dB (duration of 40 msec) separated by variable inter-
trial intervals (ITI) between 9 and 23 sec (mean = 15 sec). In 36 of the trials, the pulse was preceded 
by a 20-msec, 85-dB white-noise prepulse with stimulus-onset asynchronies (SOA) of 30, 60, and 120 
msec (12 trials each). The initial trial was a pulse-alone (PA) trial, which was separated for further 
analysis. All following trials were presented in a pseudo-randomized order. The entire test session 
lasted approximately 16 min. 
In the Bonn schizophrenia sample, each examination began with a 4-min acclimation period of 
70-dB background noise that was continued throughout the session. Participants received 73 white 
noise sound pulses at an intensity of 116 dB (duration of 40 msec) separated by variable ITI between 8 
and 22 sec (mean = 15 sec). In 36 of the trials, the pulse was preceded by a 20-msec, 86-dB white-
noise prepulse with a SOA of 120 msec. The PA initial trial was separated for further analysis. All 
following trials were presented in a pseudo-randomized order. The entire test session lasted 
approximately 20 min. 
To ensure that PPI was not influenced by smoking withdrawal, smoking ad libitum was 
permitted before testing in both laboratories (Kumari and Gray, 1999). Trial exclusion and scoring 
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criteria were identical to those used in previous studies (Quednow et al, 2006b). Subjects with 
response rejections > 50% were excluded from data analysis (healthy volunteers: n=3; schizophrenia 
patients: n=2). 
 
Statistical Analysis 
The calculation of the mean percent PPI and the habituation measures (percent habituation and 
linear gradient coefficient b) have been described in detail elsewhere (Quednow et al, 2006a; 2006b). 
For the assessment of startle habituation, PA trials were divided each into four blocks in the British 
sample and in six blocks in the German sample. Startle reactivity was assessed by the mean amplitude 
of the first block of PA trials and the mean amplitude of all PA trials. 
We did a priori- and post hoc-poweranalyses of both experiments using G*Power 3.0.3 (Faul 
et al, 2007). The actual power of both experiments was satisfactory to good: Bonn sample 72%; 
London sample 80%; Total sample 98% (see Supplementary Table A). All demographic data were 
analyzed by analysis of variance (ANOVA) with exception of frequency data. Frequency data were 
analyzed using χ2 tests. Given that sex (Swerdlow et al, 1997) and smoking (Kumari and Gray, 1999) 
could affect PPI, these variables were introduced as covariates in analyses of covariance (ANCOVA) 
of PPI data independent of the statistical significance of the covariates. All other psychophysiological 
parameters were analysed with ANOVA. On the basis of significant main effects or interactions, 
conservative post hoc comparisons according to Bonferroni were performed. The confirmatory 
statistical comparisons were carried out at a significance level set at p<.05 (two-tailed). Within the 
Pearson Product-Moment correlation analyses, the significance level was set at p<.01 (two-tailed) to 
avoid accumulation of α-error. Effect size calculations between two groups refer to Cohen's d. The 
Armitage’s Trend Test was used to analyse associations between CHRNA3 SNPs and schizophrenia. 
For a meta-analysis of the genotype effects on psychophysiological parameters across both samples 
we used Stouffer's z-score method (Whitlock, 2005).  
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Results 
London sample (healthy volunteers) 
The CHRNA3 rs1051730 and rs1317286 SNPs were in strong linkage disequilibrium 
[r2=0.967] and both genotype frequencies were distributed in accordance with Hardy-Weinberg 
Equilibrium (HWE) [rs1051730: χ2(1)=0.09; p=.77; rs1317286: χ2(1)=0.47; p=.51]. Genotype 
frequencies were also very similar between the UK and German populations. Given that the rs1051730 
and rs1317286 SNPs were in such a strong linkage disequilibrium and that their effects on the 
psychophysiological parameters were identical, we only reported the results of the rs1051730 SNP in 
the main body (for rs1317286 data see Supplementary Table B). The genotype groups of both SNPs 
did not differ regarding age, sex, education, smoking status and severity, and startle reactivity (see 
Table 1 and Supplementary Table B). 
PPI was affected by CHRNA3 genotype (see Table 1 and Supplementary Table B as well as 
Figure 1A and B). A 3×3 (SOA condition×genotype) repeated-measures ANCOVA of the rs1051730 
SNP with sex and “cigarettes per day” (CPD) as covariates revealed significant main effects for the 
factors SOA condition [F(2,90)=16.3; p<.001; ηp2=.27], sex [F(1,91)=14.4; p<.001; ηp2=.14], and 
genotype [F(2,91)=3.7; p<.05; ηp2=.08]. Bonferroni post hoc tests revealed that homozygous carriers 
of the TT-allele showed significantly lower PPI levels compared to homozygous CC-allele carriers 
[p<.05; Cohen’s d=0.79] and the heterozygous TC-allele carriers [p<.05; d=0.74]. Homozygous CC-
allele carriers and heterozygous TC-allele carriers did not differ in PPI [d=0.04]. Analyses of 
polynominal contrasts across the three genotype groups revealed a significant linear trend [p<.01] but 
no significance for a quadratic trend. The analysis regarding the rs1317286 SNPs revealed highly 
similar results (see Supplementary Table B, ANCOVA statistics and post hoc test are not shown). 
The main effect of SOA mirrors the well-known nature of PPI to increase with rising SOA 
from 30 msec through 120 msec (Blumenthal, 1999). The effect of sex reflects the known fact that 
women have generally lower PPI levels than men [pooled SOA conditions: F(1,95)=14.0; p<.001; 
ηp2=.15] (Swerdlow et al, 1997). 
There was also a significant main effect of CHRNA3 genotype on early habituation (see Table 
1 and Supplementary Table B) reflecting a diminishing habituation between the first and the second 
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block of PA trials with increasing load of the rs1051730-C and rs1317286-A alleles [polynominal 
contrasts: linear trend, p<.002]. 
Age, smoking parameters and years of education did not correlate with any of the 
psychophysiological parameters. In particular, neither the Fagerström score nor “cigarettes per day” 
were correlated with PPI (see Supplementary Table C). 
 
Bonn sample (schizophrenia patients) 
The CHRNA3 rs1051730 and rs1317286 SNPs were in complete linkage disequilibrium 
(r2=1.0) and both genotype frequencies were distributed in accordance with HWE [χ2(1)=0.05; p=.82]. 
The genotype groups did not differ regarding age, sex, education, and smoking status (see Table 2). 
Within the clinical data there was a significant main effect of genotype on the number of psychotic 
episodes, daily chlorpromazine equivalents and negative symptoms measured with the PANSS (see 
Table 2). Homozygous carriers of the TT/GG-allele displayed significantly more psychotic episodes 
than heterozygotes and received significantly higher doses of antipsychotics compared with the two 
other genotype groups. In contrast, homozygous carriers of the CC/AA-allele revealed less negative 
symptoms than heterozygotes. Further clinical data were not affected by CHRNA3 genotype. 
In contrast to all other startle parameters, PPI was again significantly influenced by CHRNA3 
genotype [ANCOVA controlled for sex and smoking status (yes/no): F(2,67)=4.3, p<.05, ηp2=0.13] 
(see Table 2 and Figure 1C). Bonferroni post-hoc tests revealed that homozygous carriers of the 
TT/GG-allele displayed significantly lower PPI levels compared to heterozygous carriers of the 
TC/GA genotype [p<.05, d=1.09]. Both homozygous groups did not significantly differ from each 
other with respect to PPI; however, the difference showed a moderate effect size [d=0.55]. PPI in the 
CC/AA group and the TC/GA group did not differ significantly differ but again the difference was 
present with a moderate effect size [d=0.55]. Analyses of polynominal contrasts across the three 
genotype groups revealed a significant quadratic trend [p<.01] but no significance for a linear trend. If 
homozygous TT/GG-allele carriers were compared to a merged group of carriers of the C/A-allele 
(TC/GA + CC/AA), both groups differ significantly regarding PPI [ANCOVA controlled for sex and 
smoking status: F(1,64)=3.94, p<.05, ηp2=0.06]. Further ANCOVAs of the three genotype groups 
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introducing chlorpromazine equivalents, number of psychotic episodes, and PANSS negative 
symptoms as further covariates still revealed significant main effects for the factor genotype. 
Correlational analysis of startle parameter and patient characteristics revealed that age was 
negatively correlated with startle reactivity [mean amplitude PA trials: r=-.38, p=.001; first block of 
PA trials: r=-.38, p=.002], indicating that older patients displayed decreased startle reactivity. 
Moreover, the startle reactivity was negatively associated with the PANSS positive score [mean 
amplitude PA trials: r=-.33, p=.007; first block of PA trials: r=-.36, p=.003], negative score [mean 
amplitude PA trials: r=-.37, p=n.s.; first block of PA trials: r=-.31, p=.01], and total score [mean 
amplitude PA trials: r=-.38, p=.002; first block of PA trials: r=-.40, p=.001]. These findings indicate 
that low startling patients displayed more severe psychotic symptoms. Finally, the number of 
psychotic episodes was inversely correlated with startle reactivity [mean amplitude PA trials: r=-.33, 
p=.007; first block of PA trials: r=-.29, p=n.s.], reflecting that more chronic patients also showed less 
startle reactivity. PPI did not correlate with any clinical or demographic data. Smoking status was also 
not correlated with PPI (see Supplementary Table C). 
 
Due to the methodological differences, German schizophrenia patients and the British controls 
could not be directly compared regarding startle parameters and PPI. However, in line with many 
previous studies, the total group of schizophrenia patients displayed significantly decreased PPI levels 
when compared with an equivalent group of healthy controls [t(114)=3.2, p<.003, controls: 56.9% PPI 
(SEM 3.2), N=46], who were assessed in Bonn with the same PPI paradigm in our previous work 
(Quednow et al, 2006b; 2008a). 
 
Meta-analysis of genotype effects on startle parameter 
In order to assess the total effect of CHRNA3 genotype on psychophysiological parameters 
across both samples we combined the p-values in a meta-analytic approach by using Stouffer's z-score 
method (see Table 4). PPI was the only parameter still showing a highly significant effect of genotype 
(p=.0027) even after Bonferroni correction for multiple phenotypes. 
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Association between CHRNA3 SNPs and schizophrenia 
There was no association of the tested CHRNA3 SNPs with a diagnosis of schizophrenia per 
se (Table 3). However, given that the control sample and the patient sample were rather small and 
have low power to detect common, low risk variants, and that the samples were recruited in different 
European countries this result should not be over interpreted. 
  13
Discussion 
The present study is the first that investigates whether sensorimotor gating depends on 
polymorphisms in the α3 subunit nAChR gene CHRNA3. We have convincingly demonstrated that the 
TT genotype of rs1051730 and the GG genotype of rs1317286 were associated with decreased PPI 
levels in both healthy volunteers and in schizophrenia patients (combined p-value 0.0027). The 
CHRNA3 rs1051730 T-allele and rs1317286 G-allele have been firmly established as risk alleles for 
tobacco dependence (Berrettini et al, 2008; Bierut et al, 2008; Caporaso et al, 2009; Saccone et al, 
2009). In our patients, these CHRNA3 SNPs were also associated with number of previous psychotic 
episodes, daily chlorpromazine dose, and negative symptoms – all indicators for severity of the illness. 
Thus, further investigation of the CHRNA3 SNPs regarding risk, course, and treatment of 
schizophrenia in larger samples is warranted. There was no indication of an association with 
schizophrenia per se, but the sample size and design of this study obviously do not allow drawing 
conclusions from that. To our knowledge, there are no published studies which have investigated 
CHRNA3/CHRNA5 gene variants for association with schizophrenia 
(http://www.schizophreniaforum.org res/sczgene, Allen et al, 2008), despite the location of these 
genes within a region on chromosome 15q possibly linked with schizophrenia (Lewis et al, 2003). The 
present demonstration that CHRNA3 gene variants are associated with an established endophenotype 
of schizophrenia might motivate a closer look at these genes in large scale association studies of 
schizophrenia. Moreover, we initially found a significant CHRNA3 effect on early habituation in the 
London sample but this effect could not be replicated in the Bonn sample. In the combined analysis of 
both samples (Table 4) we did not find an overall effect of CHRNA3 genotype on any habituation 
measure. 
At which level of the brain might mutations of the α3 nAChR subunits affect PPI? α3 nAChR 
mRNA is expressed in high densities in the prefrontal cortex (PFC), the motor and the entorhinal 
cortex, and in different nuclei of the thalamus and in lower densities also throughout the hippocampus 
(Gotti and Clementi, 2004; Paterson and Nordberg, 2000) – all structures that are also implicated in 
the mediation of PPI (Koch, 1999; Swerdlow et al, 2001). Moreover, there is evidence that α3 nAChR 
subunits regulate dopamine neurotransmission in the striatum (Quik et al, 2005; Salminen et al, 2004), 
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which is a key element of the CSPP circuitry (Koch, 1999; Swerdlow et al, 2001). Thus, the effects of 
CHRNA3 genotype on PPI could be either direct within the CSPP circuitry or indirect via the striatal 
dopamine system. 
Our findings support the view that the cholinergic system plays a key role in preattentional and 
attentional mechanisms. Recent evidence indicates that the cholinergic system has an integrating or 
synchronizing function in the central nervous system, especially in the PFC (Mansvelder et al, 2009). 
nAChRs seem to function as gatekeepers in neural transmission as pre-synaptic nAChRs tune 
inhibitory and excitatory inputs of the neuron (Mansvelder et al, 2009). This is true for modulating 
glutamatergic transmission (Vidal and Changeux, 1993) as well as for dopaminergic 
neurotransmission (Salminen et al, 2004), both of which are relevant for PPI (Koch, 1999; Swerdlow 
et al, 2001). 
Our study showed that PPI is likely to be mediated by the α3 subunit of the nAChR, and the 
results of the mecamylamine study by George and colleagues (2006) would be consistent with that. 
Given that schizophrenia patients display PPI deficits, that PPI and symptom severity are modulated 
by CHRNA3 polymorphisms, and that the nAChR system is an important neuromodulator, a future 
promising target of schizophrenia research might be the development of new medications for treating 
schizophrenia or at least cognitive deficits in schizophrenia, which affect the α3 subunits of the 
nAChR in the central nervous system. It is possible that abnormally reactive cholinergic responsivity 
is sufficient to cause an altered dopaminergic transmission (Briand et al, 2007), hence stabilizing the 
cholinergic system should also regulate the dopaminergic system, which is well-known to be affected 
in schizophrenia (Howes and Kapur, 2009). 
A measure of sensory gating is the suppression of the auditory evoked potential P50 response 
to repeated stimuli (for a review see Turetsky et al, 2007). Both P50 suppression and PPI are 
modulated by the nAChR agonist nicotine which suggests that brain cholinergic systems are involved 
in gating processes common to both paradigms (Turetsky et al, 2007). However, sensory gating 
measured by P50 suppression and sensorimotor gating measured by PPI seem to be largely 
independent phenomena because they are not correlated (Braff et al, 2007; Oranje et al, 2006; 
Schwarzkopf et al, 1993). Our results further support that P50 suppression and PPI are likely to be two 
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different inhibitory mechanisms. While P50 suppression seems to depend on α7 subunits of the 
nAChR (Freedman et al, 1997), PPI is very likely to be influenced by α3 nAChR functioning as shown 
here. Animal studies further support this hypothesis: α7 nAChR knock-out mice exhibit normal PPI 
levels and neither selective α7 nAChR agonists (GTS-21 and AR-R-17779) nor a selective α7 nAChR 
antagonist (methyllycaconitine) changed PPI in rodents (Schreiber et al, 2002; Suemaru et al, 2004). 
Based on the seminal findings of Freedman et al (1997), α7 agonists were suggested as cognitive 
enhancer in schizophrenia, but the α7 nAChR partial agonist DMXB failed to improve cognitive 
deficits is schizophrenia in a recent clinical trial (Freedman et al, 2008). However, α7 as well as α4β2 
nAChRs developed receptor insensitivity (tachyphylaxis) if there were repeatedly stimulated 
(Kuryatov et al, 2000) making these receptors less suitable targets for a continuous drug treatment 
(Harvey, 2009). In contrast, other nAChRs including the α3 subunit are largely resistant to inactivation 
after repeated stimulation (Kuryatov et al, 2000) and, thus, α3 subunits of the nAChR might be more 
promising targets for potential cognitive enhancers in schizophrenia.  
Interestingly, the effects of specific pharmacological challenges on PPI in rodents have been 
replicated in human genetic studies. Previously, it was consistently shown that dopaminergic, 
serotonergic, glutamatergic, and acetylcholinergic challenges have an impact on PPI in rodents (for 
review see Geyer et al, 2001). In recent years, it was demonstrated that polymorphisms within the 
human dopamine and serotonin systems affect PPI (Quednow et al, 2008b; 2008c; 2009; Roussos et 
al, 2008a; 2008b). The present study extends these findings to the nAChR system since we have 
clearly shown that SNPs within the α3 subunit of the nAChR also influence PPI in humans. Thus, 
these recent developments predict that polymorphisms within the glutamatergic system might also 
explain a portion of the PPI variance in the population. 
One limitation of the present study is that the two independent samples were assessed with 
slightly different PPI paradigms. This precludes a comparison of the genetic effects on PPI between 
samples. On the other hand, the replication across samples and study sites despite some procedural 
differences underscores the robustness of our findings. A second limitation is that we did not assess 
severity of smoking behavior in the schizophrenia sample assessed in Bonn. However, in contrast to 
some previous studies (Duncan et al, 2001; Swerdlow et al, 2006) the method that we used in Bonn 
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was less susceptible to the effects of smoking status on PPI, while it was proven sensitive to 
psychopathological modulations of PPI (Quednow et al, 2006a; 2006b; 2006c; 2008a; 2008b). This 
might have two reasons: 1) smoking withdrawal can decrease PPI (George et al, 2006; Kumari and 
Gray, 1999), but our subjects were allowed to smoke ad libitum before testing; 2) heavy smokers with 
schizophrenia display higher PPI levels than light- or non-smoking patients (Swerdlow et al, 2006), 
which is in line with the finding that nicotine itself could enhance PPI (Kumari et al, 1997; Postma et 
al, 2006). Since we did not assess smoking severity, the effect of smoking status alone was possibly 
too small to detect in our sample. Moreover, the investigation of smoking*genotype associations was 
not in main the focus of the present study. Thus, we think that the lack of detailed smoking data in the 
schizophrenia sample does not impair our main results presented here. A further minor limitation is 
that the low number of smokers in the London healthy controls did not allow for separate analyses of 
CHRNA3 genotype effects on PPI in smokers and nonsmokers. Thus, the power to assess smoking 
status effects on PPI as a function of CHRNA3 genotype was restricted because of the small number 
of smokers in the healthy controls (and the limited sample size in the schizophrenia sample). However, 
controlling for smoking status in statistical analyses, and excluding the 23 smokers in the British 
healthy volunteers did not alter the results [genotype effect on PPI (corrected for gender): rs1051730: 
F(2,69)=3.98; p<.05; ηp2=.10; rs1317286: F(2,69)=4.28; p<.05; ηp2=.11], suggesting that the reported 
association is not mediated or confounded by current nicotine use. Additionally, 17 of the 23 smokers 
had a Fagerström score of 0 to 2, reflecting very low addiction in most of the smoking healthy 
controls. Future studies might systematically investigate the interaction of chronic smoking and acute 
nicotine administration with genetic polymorphisms in their effect on sensory gating and attentional 
functions. Extending the self-medication hypothesis, we would hypothesize stronger nicotine effects 
on PPI in carriers of gene variants associated with smoking or with schizophrenia. Finally, we have 
only investigated two SNPs of the α3 subunits of the nAChR. Hence, mutations of other subunits and 
of nAChR haplotypes should be examined in future studies. 
One might be surprised that we did not replicate the association of smoking severity and 
CHRNA3 genotype (Berrettini et al, 2008; Bierut et al, 2008; Caporaso et al, 2009; Saccone et al, 
2009). However, the recent studies showing an association of smoking behavior with CHRNA3 
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genotype all included relatively strong smokers (e.g., Caporaso et al, 2009: 18.5 to 22.0 cigarettes per 
day), whereas we had only seven smokers in the total healthy control sample (n=96) that smoked more 
than 15 cigarettes per day. Moreover, in the schizophrenia sample we did not assess smoking severity 
and none of the previous studies reported an association of smoking status per se and CHRNA 
genotype. Lastly, in contrast to the previous association studies on smoking and CHRNA3, we have 
investigated relatively small samples indicating that the CHRNA effect on PPI seems to be much 
greater than on smoking severity. Thus, our samples were not ideal for testing smoking*CHRNA3 
genotype associations, which was however also not the focus of our study. 
In conclusion, our results confirmed previous pharmacological studies that proposed an impact 
of the nAChR system on sensorimotor gating. We have found that polymorphisms of the α3 subunits 
of the nAChR explained approximately 8% to 13% of the PPI variance in two independent samples 
suggesting a major role of α3 subunits of the nAChR in the mediation of PPI. Finally, α3-containing 
nAChRs might be explored as a new pharmacological target for cognitive enhancement in patients 
with schizophrenia. 
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Tables 
 
Table 1 Demographic data and psychophysiological parameters of British healthy human volunteers grouped according to their CHRNA3 rs1051730 genotype 
(means and standard error of means in parentheses, gender and smoking status in frequency data). Given that the rs1051730 and rs1317286 SNPs were 
in strong linkage disequilibrium [r2=0.97], the rs1317286 data are only shown in Supplementary Table B. 
 
CHRNA3 rs1051730 genotype TT TC CC Total F/Chi2 df/dferr p ηp2 
N 12 (12.5%) 40 (41.7%) 44 (45.8%) 96 (100%)     
Age 24.6 (1.1) 25.6 (1.0) 26.7 (0.9) 26.0 (0.6) 0.80 2/95 .45 .02 
Years of education 16.8 (0.9) 16.8 (0.4) 17.4 (0.6) 17.1 (0.3) 0.41 2/95 .67 .01 
Men in % 50.0% 47.5% 47.7% 47.9% 0.02 2 .99 - 
Current smokers in % 16.7% 25.0% 25.0% 24.0% 0.40 2 .82 - 
Current cigarettes smoked per day 
(only in smokers) 
12.2 (7.9), n=2 8.6 (1.7), n=10 8.7 (2.1), n=11 9.0 (1.3), n=23 0.25 2/22 .78 .02 
Fagerström Nicotine Dependence Test 
(score; only in smokers) 
2.0 (2.0), n=2 1.6 (0.7), n=10 2.0 (0.7), n=11 1.8 (0.5), n=23 0.09 2/22 .92 .01 
First block, amplitude of pulse-alone trials 
(Arbitrary units) 662 (157.2) 722 (60.6) 700 (55.5) 704 (40.3) 0.11 2/95 .90 .00 
Mean amplitude of pulse-alone trials 
(Arbitrary units) 520 (133.1) 551 (49.7) 606 (55.2) 572 (36.4) 0.40 2/95 .67 .01 
Mean percent prepulse inhibitiona 
(mean across three SOA-conditions: 30, 60 120 ms) 20.7% (4.3) 32.6% (2.3) 33.3% (2.2) 31.4% (1.6) 3.67 2/95 .03
b .08 
Percent early habituation of pulse-alone trials 
(between first and second block) 37.1% (7.4) 26.8% (4.1) 10.5% (3.9) 20.6% (22.8) 7.10 2/95 .001
c .13 
Percent total habituation of pulse-alone trials 
(between first and fourth block) 32.0% (9.9) 33.5% (5.6) 23.9% (4.5) 28.9% (3.3) 0.96 2/95 .39 .02 
Habituation of pulse-alone trials across 4 blocks 
(linear gradient coefficient b) -61.8 (28.8) -76.9 (13.1) -58.6 (11.2) -66.6 (8.3) 0.55 2/95 .58 .01 
aANCOVA, means adjusted by covariates gender and cigarettes per day. 
bBonferroni post hoc test: TT < CT & CC, p<.05 
cBonferroni post hoc test: CC < CT, p<.05; CC < TT, p<.01 
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Table 2 Demographic data and psychophysiological parameters of German schizophrenia patients grouped according to their CHRNA3 rs1051730 and 
rs1317286 genotype (means and standard error of means in parentheses, gender and smoking status in frequency data). CHRNA3 rs1051730 and 
rs1317286 polymorphisms were in complete linkage disequilibrium. 
 
CHRNA3 rs1051730 genotype TT TC CC      
CHRNA3 rs1317286 genotype GG GA AA Total F/Chi2 df/dferr p ηp2 
N 9 (13.2%) 31 (45.6%) 28 (41.2%) 68 (100%)     
Age 35.3 (2.5) 33.8 (1.6) 35.5 (2.4) 34.7 (1.3) 0.20 2/67 .81 .01 
Years of education 15.1 (0.8) 14.8 (0.5) 13.9 (0.7) 14.5 (0.3) 0.86 2/67 .43 .03 
Men in % 77.8% 71.0% 64.3% 69.1% 0.67 2 .72 - 
Current smokers in % 22.2% 54.8% 64.3% 54.4% 4.86 2 .09 - 
Patients with a first-episode in % 33.3% 71.0% 64.3% 63.2% 4.27 2 .12 - 
Age of onset 28.2 (2.5) 31.4 (1.7) 30.1 (2.0) 30.4 (1.2) 0.40 2/67 .68 .01 
Duration of illness (years) 7.1 (3.0) 2.5 (0.9) 5.8 (2.0) 4.5 (1.0) 1.76 2/67 .18 .05 
Number of episodes 3.3 (0.9) 1.6 (0.2) 2.1 (0.4) 2.0 (0.2) 3.81 2/67 .03a .11 
Medication status in % 
(unmedicated/typical/atypical antipsychotic) 0%/22%/78% 16%/16%/68% 32%/18%/50% 21%/18%/62% 5.30 4 .26 - 
Daily chlorpromazine equivalentsb 463 (68.0) 246 (32.2) 228.8 (42.8) 266 (26.0) 4.67 2/67 .01c .14 
PANSS Positive 18.7 (2.3) 19.1 (1.5) 17.3 (1.4) 18.3 (0.9) 0.42 2/67 .66 .01 
PANSS Negative 21.4 (1.6) 23.0 (1.4) 17.5 (1.4) 20.5 (0.9) 4.40 2/67 .02d .13 
PANSS General 43.1 (4.8) 43.1 (2.4) 36.8 (2.5) 40.5 (1.7) 1.83 2/67 .17 .06 
PANSS Total 83.2 (8.1) 85.6 (4.7) 71.5 (4.9) 79.5 (3.2) 2.25 2/67 .11 .07 
First block, amplitude of pulse-alone trials 
(Arbitrary units) 280 (97.7) 278 (27.6) 248.5 (36.8) 266 (23.1) 0.20 2/67 .82 .01 
Mean amplitude of pulse-alone trials 
(Arbitrary units) 238 (89.9) 221 (28.0) 179.2 (29.2) 206 (20.9) 0.61 2/67 .55 .02 
Mean percent prepulse inhibitione 
(SOA 140 ms) 20.3% (9.8) 50.6% (5.6) 35.5% (2.3) 41.9% (3.3) 4.26 2/63 .02
f .13 
Percent early habituation of pulse-alone trials 
(between first and second block) 24.0% (9.2) 23.4% (4.9) 22.6% (5.1) 23.2% (3.3) 0.01 2/67 .99 .00 
Percent total habituation of pulse-alone trials 
(between first and sixth block) 42.2% (10.7) 37.3% (6.0) 40.4% (5.5) 39.3% (3.8) 0.12 2/67 .89 .00 
Habituation of pulse-alone trials across 6 blocks 
(linear gradient coefficient b) -13.6 (4.6) -16.0 (3.5) -17.8 (3.7) -16.4 (2.3) 0.18 2/67 .84 .01 
aBonferroni post hoc test: TT/GG > TC/GA, p<.05 
bUnmedicated patients received the value zero 
cBonferroni post hoc test: TT/GG > TC/GA & CC/AA, p<.05 
dBonferroni post hoc test: CC/AA < TC/GA, p<.05 
eANCOVA, means adjusted by covariates gender and smoking status 
fBonferroni post hoc test: TT/GG < TC/GA, p<.05 
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Table 3 Frequencies of CHRNA3 rs1051730 and rs1317286 genotypes in 99 British Caucasian healthy controls and 70 German Caucasian 
schizophrenia patients (full sample inclusive of cases that dropped out for the electrophysiological analyses due to low startle data quality). 
 
CHRNA3 
Genotype Controls/Cases T-Allele C-Allele TT (n) TC (n) CC (n) Armitage’s Trend Test 
rs1051730 Controls 33.8% 66.2% 12.1% (12) 43.4% (43) 44.4% (44) 
 Schizophrenia patients 35.0% 65.0% 12.9% (9) 44.3% (31) 42.9% (30) 
Odds ratio=0.952/1.050 
chi2=0.048 
p=0.827 
  G-Allele A-Allele GG (n) GA (n) AA (n)  
rs1317286 Controls 35.4% 64.6% 14.1% (14) 42.4% (42) 43.4% (43) 
 Schizophrenia patients 35.0% 65.0% 12.9% (9) 44.3% (31) 42.9% (30) 
Odds ratio=0.975/1.026 
chi2=0.004 
p=0.948 
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Table 4 Meta-analysis of CHRNA3 genotype effects on startle parameters across both investigated 
samples (London healthy volunteers [n=96] and Bonn schizophrenia patients [n=68]). 
 
 
London sample 
mean pa 
Bonn sample p combined p-valueb 
First block, amplitude of pulse-alone trials 0.95 0.82 0.97 
Mean amplitude of pulse-alone trials 0.63 0.55 0.64 
Mean percent prepulse inhibition 0.025 0.02 0.0027 
Percent early habituation of pulse-alone trials 0.002 0.99 0.15 
Percent total habituation of pulse-alone trials 0.37 0.89 0.67 
Habituation slope of pulse-alone trials (b) 0.52 0.84 0.73 
aAveraged between rs1051730 and rs1317286 genotype 
bStouffer's z-score method 
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Figures 
 
Figure 1. The effects of CHRNA3 genotype on percent prepulse inhibition (PPI) of the acoustic startle 
response in healthy human volunteers and schizophrenia patients (means and SEM, adjusted for sex 
and smoking): (A) CHRNA3 rs1051730 polymorphism in 96 British healthy human volunteers 
(Bonferroni post hoc test vs. TT allele group: *p < .05), (B) CHRNA3 rs1317286 polymorphism in 96 
British healthy human volunteers (Bonferroni post hoc test vs. GG allele group: *p < .05), and (C) the 
completely associated CHRNA3 rs1051730 and rs1317286 polymorphisms in German schizophrenia 
patients (Bonferroni post hoc test vs. TT/GG allele group: *p < .05).  
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CHRNA3 polymorphisms in schizophrenia and healthy volunteers” 
 
Genotyping 
From the British healthy volunteers, DNA was obtained from venal blood or buccal swabs using 
established procedures (Freeman et al, 2003). The CHRNA3 SNP genotyping assays (rs1051730 and 
rs1317286) were run as submicroliter polymerase chain reaction–based assays on Array Tape 
(http://www.douglasscientific.com) at PreventionGenetics (Marshfield, Wisconsin). For both SNPs 
they used InvaderPlus reactions from Third Wave Technologies (Madison, Wisconsin). To improve 
genotyping reliability, many samples of similar DNA quality and concentration were genotyped at the 
same time. Genotyping was successful in 92.5% of subjects for each of both CHRNA3 SNPs. 
 
In the German schizophrenia patients, DNA for genotyping was isolated either from EDTA acid 
anticoagulated blood or permanent cell cultures received after transforming the lymphocytes with 
Epstein-Barr virus. The isolation of the DNA followed the QIAGEN protocol for the Blood & Cell 
Culture DNA Maxi Kit (QIAGEN, Hilden, Germany). PCR was performed using 12.5 ng of DNA. 
The two CHRNA3 SNPs (rs1051730 and rs1317286) were analyzed by Taqman® Assays. The 
procedure followed the protocol for Taqman® Assays with the use of Taqman® Universal PCR 
MasterMix, No AmpErase UNG (Applied Biosystems, Foster City, CA, USA). Each assay consists of 
the unlabeled forward primer and the unlabeled reverse primer and two reporters that are dye-labeled 
with FAM and VIC. The assays are designed for allelic discrimination of specific SNPs. All alleles of 
each SNP were scored in a single-well by measuring the fluorescence at the end of the PCR using a 
Tecan Ultra 384 reader (Tecan, Crailsheim, Germany). Excitation- and emission-wavelengths for the 
FAM labeled probes were 485 and 535 nm and for the VIC labeled probes 535 and 590 nm, 
respectively. Genotyping was successful in 95.9% of subjects for each of both CHRNA3 SNPs. 
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Table A Post hoc-power analyses of both experiments. 
 
Post hoc power analysis Healthy volunteers Schizophrenia patients Total 
Cohens effect size f (measured) 0.29 0.39 0.34 
Alpha error (assumed) 0.05 0.05 0.05 
Actual power (1- beta error) 0.72 0.80 0.98 
Sample size 96 68 166 
Critical F 3.09 3.14 3.05 
Number of groups 3 3 3 
*assumed according to our previous results (e.g., Quednow et al, 2009), 
f=0.33 ≈ 10% explained variance 
 
 
 
Table B Demographic data and psychophysiological parameters of British healthy human volunteers grouped according to their CHRNA3 rs1317286 
genotype (means and standard error of means in parentheses, gender and smoking status in frequency data). 
 
CHRNA3 rs1317286 genotype GG GA AA Total F/Chi2 df/dferr p ηp2 
N 13 (13.5%) 40 (41.7%) 43 (44.8%) 96 (100%)     
Age 24.5 (1.0) 25.5 (1.0) 26.8 (0.9) 26.0 (0.6) 1.06 2/95 .35 .02 
Years of education 16.5 (0.9) 16.9 (0.4) 17.4 (0.6) 17.1 (0.3) 0.59 2/95 .56 .01 
Men in % 46.2% 47.5% 48.8% 47.9% 0.03 2 .98 - 
Current smokers in % 15.4% 25.0% 25.6% 24.0% 0.61 2 .74 - 
Current cigarettes smoked per day 
(only in smokers) 
12.2 (7.9), n=2 8.6 (1.7), n=10 8.7 (2.1), n=11 9.0 (1.3), n=23 0.25 2/22 .78 .02 
Fagerström Nicotine Dependence Test 
(score; only in smokers) 
2.0 (2.0), n=2 1.6 (0.7), n=10 2.0 (0.7), n=11 1.8 (0.5), n=23 0.09 2/22 .92 .01 
First block, amplitude of pulse-alone trials 
(Arbitrary units) 691 (147.5) 706 (60.7) 707 (56.3) 
704 (40.3) 0.01 2/95 .99 .00 
Mean amplitude of pulse-alone trials 
(Arbitrary units) 558 (128.3) 533 (48.6) 613 (56.0) 
572 (36.4) 0.54 2/95 .59 .01 
Mean percent prepulse inhibitiona 
(mean across three SOA-conditions: 30, 60, 120 ms) 
20.9% (4.1) 32.2% (2.3) 33.9% (2.3) 31.4% (1.6) 3.94 2/95 .02b .08 
Percent early habituation of pulse-alone trials 
(between first and second block) 
35.7% (7.0) 26.4% (4.1) 10.7% (3.9) 20.6% (22.8) 6.33 2/95 .003c .12 
Percent total habituation of pulse-alone trials 
(between first and fourth block) 
29.4% (9.5) 34.3% (5.5) 23.8% (4.6) 28.9% (3.3) 1.07 2/95 .35 .02 
Habituation of pulse-alone trials across 4 blocks 
(linear gradient coefficient b) 
-54.7 (27.4) -79.0 (12.9) -58.8 (11.5) -66.6 (8.3) 0.80 2/95 .45 .02 
aANCOVA, means adjusted by covariates gender and cigarettes per day. 
bBonferroni post hoc test: GG < GA & AA, p<.05 
cBonferroni post hoc test: AA < GA, p<.05; AA < GG, p<.01 
Table C Correlation values (r) between smoking behavior and prepulse inhibition (PPI) in both investigated 
samples (London healthy volunteers [n=96] and Bonn schizophrenia patients [n=68]). 
 
London samplea Fagerström score  Cigarettes per day 
PPI, SOA 30 ms -.087 .020 
PPI, SOA 60 ms .004 .016 
PPI, SOA 120 ms .101 .150 
PPI, total  .016 .078 
Bonn Sampleb Smoking status (yes/no)  
PPI, SOA 120 ms .052  
aPearson product-moment correlation  
bSpearman’s rho  
 
 
 
